Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer
A Randomized Phase II Trial of Doxil With or Without Dexamethasone in Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer
Sponsor: Ortho Biotech, Inc.
Terminated
Slow accrual
Other terminated trials from Ortho Biotech, Inc.
- Lymphoma · Phase PHASE2 · Sep 2011
- Drug Resistance · Phase PHASE3 · Feb 2009
- Subarachnoid Hemorrhage · Phase PHASE4 · Feb 2009
- T-Cell Lymphoma · Phase NA · Oct 2007
- Nerve Compression Syndromes · Phase PHASE2/PHASE3 · Jul 2007
More terminations from Ortho Biotech, Inc.
Other Prostate Cancer trials with similar outcome
A PHASE2 clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Ortho Biotech, Inc. and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ortho Biotech, Inc.
- University of Kentucky
For direct contact, visit the study record on ClinicalTrials.gov .